MCID: CNG029
MIFTS: 34

Congenital Mesoblastic Nephroma malady

Categories: Rare diseases, Nephrological diseases, Cancer diseases

Aliases & Classifications for Congenital Mesoblastic Nephroma

About this section
Sources:
10Disease Ontology, 45NIH Rare Diseases, 12DISEASES, 51Orphanet, 65UMLS, 36MeSH, 42NCIt, 28ICD10 via Orphanet, 37MESH via Orphanet, 66UMLS via Orphanet
See all MalaCards sources

Aliases & Descriptions for Congenital Mesoblastic Nephroma:

Name: Congenital Mesoblastic Nephroma 10 45 12 51 65
 
Nephroma, Mesoblastic 36

Classifications:



External Ids:

Disease Ontology10 DOID:4773
MeSH36 D018201
NCIt42 C6569
Orphanet51 2665
ICD10 via Orphanet28 D41.0
MESH via Orphanet37 D018201
UMLS via Orphanet66 C1332965
UMLS65 C1332965

Summaries for Congenital Mesoblastic Nephroma

About this section
Wikipedia:68 Congenital mesoblastic nephroma is a type of kidney tumor that is usually found before birth by... more...

MalaCards based summary: Congenital Mesoblastic Nephroma, also known as nephroma, mesoblastic, is related to classic congenital mesoblastic nephroma and cellular congenital mesoblastic nephroma. An important gene associated with Congenital Mesoblastic Nephroma is ETV6 (ETS Variant 6), and among its related pathways are Cardiac Progenitor Differentiation and p70S6K Signaling. Affiliated tissues include kidney, liver and lung, and related mouse phenotypes are embryo and no phenotypic analysis.

Related Diseases for Congenital Mesoblastic Nephroma

About this section

Diseases in the Adult Mesoblastic Nephroma family:

congenital mesoblastic nephroma

Diseases related to Congenital Mesoblastic Nephroma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 171)
idRelated DiseaseScoreTop Affiliating Genes
1classic congenital mesoblastic nephroma34.5ETV6, NTRK3
2cellular congenital mesoblastic nephroma12.7
3hepatitis10.5
4prostatitis10.5
5prostate cancer10.4
6breast cancer10.4
7alzheimer disease10.4
8leukemia10.4
9tooth agenesis10.4
10dermatitis10.4
11thyroiditis10.4
12colon mucinous adenocarcinoma10.3ETV6, IGF2
13thymus adenocarcinoma10.3ETV6, NTRK3
14conventional fibrosarcoma10.3NTRK3, WT1
15clitoris cancer10.3IGF2, WT1
16acute myeloid leukemia with inv3(p21;q26.2) or t(3;3)(p21;q26.2)10.3ETV6, KIT
17small intestinal sarcoma10.3IGF2, KIT
18cutaneous leiomyosarcoma10.3IGF2, KIT
19nephrogenic adenofibroma10.3LATS1, WT1
20aortitis10.3LATS1, WT1
21neuroblastoma10.3
22systemic lupus erythematosus10.3
23malaria10.3
24obesity10.3
25hodgkin lymphoma10.3
26abetalipoproteinemia10.3
27osteoporosis10.3
28netherton syndrome10.3
29oculodentodigital dysplasia10.3
30keratitis10.3
31phenylketonuria10.3
32endometrial cancer10.3
33insulin-like growth factor i10.3
34pancreatic cancer10.3
35epidermodysplasia verruciformis10.3
36tendinopathy10.3
37pulmonary hypertension10.3
38acne10.3
39b-cell lymphomas10.3
40bone fracture10.3
41charcot-marie-tooth disease10.3
42cutaneous leishmaniasis10.3
43diffuse large b-cell lymphoma10.3
44glomerulonephritis10.3
45glycogen storage disease10.3
46polycystic ovary syndrome10.3
47retinal ischemia10.3
48spinal muscular atrophy10.3
49pachyonychia congenita10.3
50lymphoma10.3

Graphical network of the top 20 diseases related to Congenital Mesoblastic Nephroma:



Diseases related to congenital mesoblastic nephroma

Symptoms for Congenital Mesoblastic Nephroma

About this section

Drugs & Therapeutics for Congenital Mesoblastic Nephroma

About this section

Drugs for Congenital Mesoblastic Nephroma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 25)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Fentanylapproved, illicit, investigationalPhase 3705437-38-73345
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-Phenethyl-4-N-propionylanilinopiperidine
437-38-7
5-22-08-00049 (Beilstein Handbook Reference)
80832-90-2
990-73-8 (citrate)
AC1L1FQ2
Abstral
Actiq
BIDD:GT0555
BRN 0494484
CHEBI:119915
CHEMBL596
CID3345
D00320
DB00813
Duragesic
Duragesic (TN)
Duragesic-100
Duragesic-12
Duragesic-25
Duragesic-50
Duragesic-75
Durogesic
EINECS 207-113-6
Fentanest
Fentanil
Fentanil [DCIT]
Fentanila
Fentanila [INN-Spanish]
Fentanilo
Fentanyl
Fentanyl (JAN/USAN/INN)
Fentanyl - Novaplus
Fentanyl Citrate
Fentanyl [INN:BAN]
Fentanyl citrate
Fentanyl-100
 
Fentanyl-12
Fentanyl-25
Fentanyl-50
Fentanyl-75
Fentanylum
Fentanylum [INN-Latin]
HSDB 3329
IONSYS
JNS020QD
L001275
LS-124439
Lazanda
Matrifen
MolPort-003-847-369
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide
N-Phenethyl-4-(N-propionylanilino)piperidine
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
NCGC00168252-01
Nasalfent
Oprea1_152073
Oprea1_207148
PDSP1_000860
PDSP2_000846
Pentanyl
Phentanyl
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)
R 4263
Rapinyl
Sentonil
Sublimase
Sublimaze
Subsys
UNII-UF599785JZ
fentanyl
2Liver ExtractsPhase 3, Phase 1, Phase 23572
3pancreatic polypeptidePhase 320
4Peripheral Nervous System AgentsPhase 318510
5AnalgesicsPhase 39358
6NarcoticsPhase 32709
7AnestheticsPhase 37385
8Anesthetics, GeneralPhase 32274
9Analgesics, OpioidPhase 32304
10Anesthetics, IntravenousPhase 31943
11Central Nervous System DepressantsPhase 310016
12ColaNutraceuticalPhase 31768
13
Dasatinibapproved, investigationalPhase 1, Phase 2268302962-49-83062316
Synonyms:
(18F)-N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
1N1
2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide
302962-49-8
AC1MI3ET
AC1Q2P0C
AmbotzLS-1203
Anh. dasatinib
Anhydrous dasatinib
BCB03_000715
BMS 354825
BMS dasatinib
BMS-354825
BMS-354825, Sprycel, BMS354825, Dasatinib
BMS354825
C488369
CHEBI:49375
CHEMBL1421
CID3062316
D03658
DB01254
Dasatinib
Dasatinib (USAN)
Dasatinib (anh.)
Dasatinib [USAN]
Dasatinib anhydrous
Dasatinib, BMS 354825
 
Dasatinibum
EC-000.2122
EN002710
FT-0084503
I14-1972
Kinome_3650
LS-186641
LS-187028
LS-187773
MolPort-003-846-143
N-(2-CHLORO-6-METHYLPHENYL)-2-({6-[4-(2-HYDROXYETHYL)PIPERAZIN-1-YL]-2-METHYLPYRIMIDIN-4-YL}AMINO)-1,3-THIAZOLE-5-CARBOXAMIDE
N-(2-CHLORO-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide
N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, monohydrate
N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide
N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide
NCGC00181129-01
NSC-732517
NSC732517
S1021_Selleck
SPRYCEL (TN)
Sprycel
Spyrcel
UNII-X78UG0A0RN
dasatinib
dasatinibum
nchembio.117-comp11
nchembio.162-comp4
nchembio.332-comp1
14
CarboplatinapprovedPhase 1, Phase 2188541575-94-410339178, 498142, 38904
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
Carbopaltin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Cbdca
Cyclobutane-1,1-dicarboxylate
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
DivK1c_000892
EINECS 255-446-0
EU-0100230
Ercar
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
IUPAC: Azane
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
 
JM 8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
LS-117689
Lopac-C-2538
Lopac0_000230
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
NINDS_000892
NSC 201345
NSC 241240
NSC-241240
NSC201345
NSC241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
Platinum(II), (1, 1-cyclobutanedicar
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Platinum, {diammine[1,1-cyclobut
S1215_Selleck
SPBio_000716
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
Spectrum_001529
UNII-BG3F62OND5
azanide
carboplatin
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
cyclobutane-1,1-dicarboxylic acid
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
platinum(2+)
15
MechlorethamineapprovedPhase 1, Phase 230951-75-24033
Synonyms:
.Beta.,.beta.'-Dichlorodiethyl-N-methylamine
1, 5-Dichloro-3-methyl-3-azapentane hydrochloride
126-85-2 (N-oxide)
2,2'-Dichloro-N-me
2,2'-Dichloro-N-methyldiethylamine
2,2'-Dichlorodiethyl-methylamine
2,2'-dichloro-N-methyldiethylamine
2-Chloro-N-(2-chloroethyl)-N-methylethanamine
302-70-5 (N-oxide, hydrochloride)
51-75-2
55-86-7 (HYDROCHLORIDE)
AC1L1H9H
Antimit
BRN 0605323
BSPBio_001947
Bis(2-chloroethyl)methylamine
Bis(beta-chloroethyl) methylamine
Bis(beta-chloroethyl)methylamine
C07115
C5H11Cl2N
CCRIS 447
CHEBI:28925
CHEMBL427
CID4033
Carolysine
Caryolysin
Caryolysine
Chloramine (the nitrogen mustard)
Chlorethazine
Chlormethine
Chlormethine (INN)
Chlormethine [INN:BAN]
Chlormethinum [INN-Latin]
Cloramin
Clormetina
Clormetina [INN-Spanish]
D07671
DB00888
Di(2-chloroethyl)methylamine
Dichlor amine
Dichloren
DivK1c_000759
EINECS 200-120-5
ENT-25294
Embechine
Embichin
HMS1920J15
HMS2091B04
HMS502F21
HN-2
HN2
HSDB 5083
I14-8708
IBS-L0033631
IDI1_000759
KBio1_000759
KBio2_001369
KBio2_003937
KBio2_006505
KBio3_001447
KBioGR_001448
 
KBioSS_001369
LS-7559
MBA
Me chloroethamine
Mebichloramine
Mechlorethamine
Mechlorethamine hydrochloride
Mechlorethanamine
Mechloroethamine
Mecloretamina
Mecloretamina [Italian]
Methylbis(2-chloroethyl)amine
Methylbis(beta-chloroethyl)amine
Methyldi(2-chloroethyl)amine
Mitoxine (*Hydrochloride*)
MolPort-001-785-592
Mustargen
Mustine
Mustine note
Mutagen
N,N-Bis(2-chloroethyl)-N-methylamine
N,N-Bis(2-chloroethyl)methylamine
N,N-Di(chloroethyl)methylamine
N-Lost
N-Methyl lost
N-Methyl-2,2'-dichlorodiethylamine
N-Methyl-bis(2-chloroethyl)amine
N-Methyl-bis(beta-chloroethyl)amine
N-Methyl-bis-chloraethylamin
N-Methyl-bis-chloraethylamin [German]
N-Methyl-lost
N-Methyl-lost [German]
N-methyl-bis(2-chloroethyl)amine
NCGC00091835-02
NCGC00091835-03
NCGC00091835-04
NCGC00091835-05
NCI60_041682
NINDS_000759
NSC762
Nitol (*Hydrochloride*)
Nitrogen mustard
Nitrogen mustard (HN-2)
Nitrogranulogen
SPBio_000496
SPECTRUM1500375
Spectrum2_000448
Spectrum3_000484
Spectrum4_000924
Spectrum5_001702
Spectrum_000889
Stickstofflost (*Hydrochloride*)
Stickstofflost (ebewe)
T 1024
T-1024
TL 146
UNII-50D9XSG0VR
Valchlor
beta,Beta'-dichlorodiethyl-N-methylamine
beta,beta'-Dichlorodiethyl-N-methylamine
mechlorethamine
thyldiethylamine
╬▓,╬▓'-dichlorodiethyl-N-methylamine
16
IfosfamideapprovedPhase 1, Phase 23713778-73-23690
Synonyms:
(+-)-Ifosfamid
(+-)-Ifosphamide
(+-)-Tetrahydro-N,3-bis(2-chloroethyl)-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
(D,L)-Ifosfamide
(R,S)-Ifosphamide
(R,S)-N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide
1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide
2,3-(N,N(sup 1)-Bis(2-chloroethyl)diamido)-1,3,2-oxazaphosphoridinoxyd
2,3-N,N(sup 1)-Bis(2-chloroethyl)diamido-1,3,2-oxazaphosphoridinoxyd
2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis( 2-chloroethyl)tetrahydro-, 2-oxide
2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-, 2-oxide
2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide
2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide (8CI)
2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide
3,} 2-oxazaphosphorine oxide
3-(2-Chloroethyl)-2-((2-chloroethyl)amino)perhydro-2H-1,3,2-oxazaphosphorine oxide
3-(2-Chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorine oxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorineoxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2- oxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
36341-88-5
3778-73-2
84711-20-6
A 4942
AB00513932
AC-2113
AC1L1GHW
ASTA Z 4942
Ambap3778-73-2
Asta Z 4942
BPBio1_000865
BRN 0611835
BSPBio_000785
C07047
CAS-3778-73-2
CCRIS 352
CHEBI:5864
CHEMBL1024
CID3690
Cyfos
D00343
D007069
DB01181
EINECS 223-237-3
HMS1570H07
HMS2090M12
HMS2093N07
HSDB 7023
Holoxan
Holoxan 1000
I-Phosphamide
I06-0494
IFEX (TN)
Ifex
Ifosfamid
Ifosfamida
Ifosfamida [INN-Spanish]
Ifosfamide
 
Ifosfamide (JAN/USP/INN)
Ifosfamide Sterile
Ifosfamide [USAN:INN:BAN:JAN]
Ifosfamidum
Ifosfamidum [INN-Latin]
Ifosphamide
Ifsofamide
Iphosphamid
Iphosphamid(e)
Iphosphamide
Iso Endoxan
Iso-Endoxan
Isoendoxan
Isofosfamide
Isophosphamide
Isosfamide
LS-102
LS-99799
MJF 9325
MJF-9325
MLS002154021
Mitoxana
Mitoxana, Ifex, Ifosfamide
MolPort-003-666-704
N,3-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
N,N-Bis(beta-chloroethyl)-amino-N',O-propylene-phosphoric acid ester diamide
N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid
N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid [German]
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylen ephosphoric acid diamide
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylene phosphoric acid ester diamide
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid diamide
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid ester diamide
N-(2-Chloroethyl)-N-(3-(2-chloroethyl)-2-oxido-1,3,2-oxazaphosphinan-2-yl)amine
NCGC00016639-01
NCGC00179435-01
NCI-C01638
NCI60_000233
NPFAPI-04
NSC 109,724
NSC 109724
NSC-109,724
NSC-109724
NSC109,724
NSC109724
Naxamide
Prestwick0_000833
Prestwick1_000833
Prestwick2_000833
Prestwick3_000833
S1302_Selleck
SMR001233348
SPBio_002706
STL058690
UNII-UM20QQM95Y
WLN: T6NPOTJ AM2G BO B2G
Z 4942
Z-4942
Z4942
ifosfamide
isosfamide
{3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,
17
EtoposideapprovedPhase 1, Phase 2116933419-42-036462
Synonyms:
(-)-Etoposide
121471-01-0
136598-18-0
201594-04-9
33419-42-0
35317-32-9
4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside
4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin
4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside
4-Demethylepipodophyllotoxin-.beta.-D-ethylideneglucoside
51854-34-3
76576-58-4
9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
AB00438905
AC1L1FN8
AC1L1VT3
AC1L6246
AC1NR4OG
AC1O4WGG
AC1O7M1N
AC1Q47JJ
Ambap33419-42-0
BPBio1_000673
BRD-K37798499-001-02-5
BSPBio_000611
Bio1_000489
Bio1_000978
Bio1_001467
C01576
CCRIS 2392
CHEBI:4911
CHEBI:588795
CHEMBL44657
CID11758093
CID284997
CID3310
CID36462
CID5284558
CID6419930
CID6610299
CPD000112002
D00125
DB00773
DEMETHY-EPIPODOPHYLLOTOXIN,ETHYLIDENE GLUCOSIDE,
Demethyl Epipodophyllotoxin Ethylidine Glucoside
Demethyl-epiodophyllotoxin ethylidene glucoside
Demethylepipodophyllotoxin-beta-D-ethylideneglucoside
E0675
E1383_SIGMA
EINECS 251-509-1
EPE
EPEG
ETOP
Epipodophyllotoxin
Epipodophyllotoxin VP-16213
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-.beta.-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-.beta.-D-glucopyranoside)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
Eposide
Eposin
Eposin, Vepesid, VP-16, Toposar, Etoposide
 
Etopol
Etopophos
Etopophos (phosphate salt)
Etoposid
Etoposide
Etoposide (JP15/USP/INN)
Etoposide (VP16)
Etoposide Phosphate
Etoposide [USAN:INN:BAN:JAN]
Etoposido
Etoposido [INN-Spanish]
Etoposidum
Etoposidum [INN-Latin]
Etosid
HMS1569O13
HMS2052N05
HMS2089F14
HSDB 6517
I06-0248
KBioSS_002410
LS-1214
Lastet
MLS000049957
MLS001074951
MLS001424283
MLS002153463
MLS002207239
MLS002222184
MolPort-003-983-431
MolPort-004-905-001
MolPort-004-955-161
NCGC00025056-02
NChemBio.2007.10-comp19
NK 171
NSC 141540
NSC-141540
NSC141540
Prestwick0_000396
Prestwick1_000396
Prestwick2_000396
Prestwick3_000396
Prestwick_211
S1225_Selleck
SAM001246880
SMR000112002
SPBio_002532
ST056353
Toposar
UNII-6PLQ3CP4P3
VP 16
VP 16 (pharmaceutical)
VP 16-213
VP 16213
VP-16
VP-16-213
VePESID (TN)
VePesid
Vepesid
Vepesid J
Vepeside
ZINC03830818
ZINC03938684
Zuyeyidal
etoposide
nchembio.573-comp8
nchembio873-comp2
trans-Etoposide
18Protein Kinase InhibitorsPhase 1, Phase 23162
19Topoisomerase InhibitorsPhase 1, Phase 24081
20Isophosphamide mustardPhase 1, Phase 2371
21Alkylating AgentsPhase 1, Phase 23582
22Antineoplastic Agents, AlkylatingPhase 1, Phase 23406
23Antineoplastic Agents, PhytogenicPhase 1, Phase 24294
24Etoposide phosphatePhase 1, Phase 21169
25tyrosineNutraceuticalPhase 1596

Interventional clinical trials:

idNameStatusNCT IDPhase
1Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainCompletedNCT00538850Phase 3
2Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid TumorsActive, not recruitingNCT00788125Phase 1, Phase 2
3Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS TumorsRecruitingNCT02650401Phase 1
4Study of Kidney Tumors in Younger PatientsRecruitingNCT00898365
5Study of Genes and Environment in Patients With Cancer in East Anglia, Trent, or West Midlands Regions of the United KingdomRecruitingNCT00757614
6Studying Biomarkers in Samples From Younger Patients With Kidney CancerWithdrawnNCT01642095

Search NIH Clinical Center for Congenital Mesoblastic Nephroma


Cochrane evidence based reviews: nephroma, mesoblastic

Genetic Tests for Congenital Mesoblastic Nephroma

About this section

Anatomical Context for Congenital Mesoblastic Nephroma

About this section

MalaCards organs/tissues related to Congenital Mesoblastic Nephroma:

33
Kidney, Liver, Lung, Breast, Monocytes, Testes, Prostate

Animal Models for Congenital Mesoblastic Nephroma or affiliated genes

About this section

MGI Mouse Phenotypes related to Congenital Mesoblastic Nephroma:

38 (show all 14)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053808.5ETV6, IGF2, KIT, SMARCB1, WT1
2MP:00030128.5ETV6, IGF2, KIT, LATS1, NTRK3, WT1
3MP:00020068.4ETV6, KIT, LATS1, SMARCB1, WT1
4MP:00053708.4IGF2, KIT, LATS1, SMARCB1, WT1
5MP:00028738.4ETV6, KIT, LATS1, NTRK3, REN, WT1
6MP:00053897.8IGF2, KIT, LATS1, REN, SMARCB1, WT1
7MP:00053877.7ETV6, IGF2, KIT, REN, SMARCB1, WT1
8MP:00053977.7ETV6, IGF2, KIT, REN, SMARCB1, WT1
9MP:00053767.4ETV6, IGF2, KIT, LATS1, REN, SMARCB1
10MP:00107687.0ETV6, IGF2, KIT, LATS1, NTRK3, REN
11MP:00053787.0ETV6, IGF2, KIT, LATS1, NTRK3, REN
12MP:00053857.0ETV6, IGF2, KIT, LATS1, NTRK3, REN

Publications for Congenital Mesoblastic Nephroma

About this section

Articles related to Congenital Mesoblastic Nephroma:

(show top 50)    (show all 139)
idTitleAuthorsYear
1
Butanol-Partitioned Extraction from Aqueous Extract of Gracilaria tenuistipitata Inhibits Cell Proliferation of Oral Cancer Cells Involving Apoptosis and Oxidative Stress. (27138906)
2016
2
The Use of Hydroxyurea and Leukapheresis in Childhood Acute Leukemia With Hyperleukocytosis. (27164521)
2016
3
Simvastatin downregulates expression of TGF-I^RII and inhibits proliferation of A549 cells via ERK. (25631750)
2015
4
Altered autonomic nervous system reactivity to pain in trigeminal neuralgia. (25804249)
2015
5
Dipeptidyl Peptidase 4: A New Link between Diabetes Mellitus and Atherosclerosis? (26146634)
2015
6
Marjolin's Ulcer in a Post Burn Scar of the Hand. (26435998)
2015
7
Liver transplantation for alcoholic liver disease. (24393837)
2014
8
An ethicist's commentary on the dog with Cushing's syndrome - A reply. (23997256)
2013
9
Ferrara ring segments implantation for treating keratoconus. (23166869)
2012
10
Pyoderma gangrenosum following trauma of the knee: a case of pathergy and review of orthopaedic cases. (20638661)
2011
11
Treatment of chronic graft-versus-host disease: Past, present and future. (22065969)
2011
12
Targeting IL-13RI+2 in human pancreatic ductal adenocarcinoma with combination therapy of IL-13-PE and gemcitabine. (20473925)
2011
13
Modulation of TRPM6 and Na(+)/Mg(2+) exchange in mammary epithelial cells in response to variations of magnesium availability. (19890837)
2010
14
Treatment and complications in flaccid neuromuscular scoliosis (Duchenne muscular dystrophy and spinal muscular atrophy) with posterior-only pedicle screw instrumentation. (19885687)
2010
15
Mouse embryonic fibroblasts from CD38 knockout mice are resistant to oxidative stresses through inhibition of reactive oxygen species production and Ca(2+) overload. (20638362)
2010
16
Lessons from 30 years of selective screening for tetrahydrobiopterin deficiency. (20458544)
2010
17
Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. (19602710)
2009
18
Effects of cholinesterase inhibition on brain white matter volume in Alzheimer's disease. (19444953)
2009
19
Inhibition of HIV-1 integrase nuclear import and replication by a peptide bearing integrase putative nuclear localization signal. (19961612)
2009
20
Implication of the Akt2/survivin pathway as a critical target in paclitaxel treatment in human ovarian cancer cells. (18842333)
2009
21
Evidence for association of chromosome 10 open reading frame (C10orf27) gene polymorphisms and multiple sclerosis. (18208870)
2008
22
Glycosylation changes in hFUT1 transgenic mice increase TCR signaling and apoptosis resulting in thymocyte maturation arrest. (18155296)
2008
23
Association of killer cell immunoglobulin-like receptor genotypes with susceptibility to endometriosis. (17997746)
2007
24
Prevention of TGF-beta-induced apoptosis by interlukin-4 through Akt activation and p70S6K survival signaling pathways. (17624592)
2007
25
Intrahepatic cholangiocarcinoma arising in cirrhotic liver frequently expressed p63-positive basal/stem-cell phenotype. (16377099)
2006
26
Tumor necrosis factor and lymphotoxin alfa genetic polymorphisms and outcome in pediatric patients with non-Hodgkin's lymphoma: results from Berlin-Frankfurt-MA1nster Trial NHL-BFM 95. (16293872)
2005
27
Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. (15456405)
2005
28
BCL11B functionally associates with the NuRD complex in T lymphocytes to repress targeted promoter. (16091750)
2005
29
Nitric oxide production in HIV-1 infected patients receiving intermittent cycles of interleukin-2 and antiretrovirals. (15248139)
2004
30
Compression forces generated by actin comet tails on lipid vesicles. (12738883)
2003
31
Juvenile-onset glycogen storage disease type II with novel mutations in acid alpha-glucosidase gene. (12601120)
2003
32
Pyoderma gangrenosum. (17642880)
2003
33
Epidermal growth factor receptor-targeted therapy in colorectal cancer. (12422309)
2002
34
Asperger syndrome: tests of right hemisphere functioning and interhemispheric communication. (12199132)
2002
35
Pro-inflammatory cytokine response of the fluid contents of spermatoceles and epididymal cysts. (11966578)
2002
36
TSC2 missense mutations inhibit tuberin phosphorylation and prevent formation of the tuberin-hamartin complex. (11741832)
2001
37
Piriformis syndrome. (10741359)
2000
38
The relationship between circulating sialyl Tn antigen and polypoid or nonpolypoid growth characteristics in colorectal cancer. (11003566)
2000
39
Mutations of the human P gene associated with type II oculocutaneous albinism (OCA2). (10671067)
1998
40
Allogeneic cell-mediated and cytokine-activated immunotherapy for malignant lymphoma at the stage of minimal residual disease after autologous stem cell transplantation. (9807740)
1998
41
Expression, induction, and catalytic activity of the ethanol-inducible cytochrome P450 (CYP2E1) in human fetal liver and hepatocytes. (8632758)
1996
42
What is your diagnosis? Supraspinous bursitis (fistulous withers). (8641943)
1996
43
Interleukin-1 receptor antagonist in the fetomaternal compartment. (7780241)
1995
44
Evaluation of the expression levels of nm23-H1 mRNA in primary breast cancer, benign breast disease, axillary lymph nodes and normal breast tissue. (7892043)
1994
45
Receptor-activated calcium influx in human monocytes exposed to monocyte chemotactic protein-1 and related cytokines. (7679430)
1993
46
Neonatal jaundice. (2369801)
1990
47
Addison's disease and primary antiphospholipid syndrome. (2571808)
1989
48
Isolation and characterization of HTLV-I from symptomatic family members with tropical spastic paraparesis (HTLV-I encephalomyeloneuropathy). (2474617)
1989
49
Ovarian mucinous cystadenocarcinoma of low malignant potential associated with a mature cystic teratoma. (3338676)
1988
50
Embryonal rhabdomyosarcoma of the kidney. (894819)
1977

Variations for Congenital Mesoblastic Nephroma

About this section

Expression for genes affiliated with Congenital Mesoblastic Nephroma

About this section
Search GEO for disease gene expression data for Congenital Mesoblastic Nephroma.

Pathways for genes affiliated with Congenital Mesoblastic Nephroma

About this section

Pathways related to Congenital Mesoblastic Nephroma according to GeneCards Suite gene sharing:

idSuper pathwaysScoreTop Affiliating Genes
19.6IGF2, KIT
2
Show member pathways
8.7IGF2, KIT, NTRK3, REN

GO Terms for genes affiliated with Congenital Mesoblastic Nephroma

About this section

Biological processes related to Congenital Mesoblastic Nephroma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1positive regulation of peptidyl-serine phosphorylationGO:00331389.7LATS1, NTRK3
2positive regulation of sequence-specific DNA binding transcription factor activityGO:00510918.8KIT, SMARCB1

Sources for Congenital Mesoblastic Nephroma

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet